Aceragen | IDRA - Passivo Circulante



Passivo Circulante Alterar Data
Abbott USD 18.38B 1.88B 2026-03
Agenus USD 231.82M 17.42M 2026-06
Alnylam Pharmaceuticals USD 1.51B 163.04M 2026-06
Alterity Therapeutics Limited AUD 1.73M 2.77M 2025-12
Amgen USD 25.5B 547M 2026-06
Biogen USD 3.92B 918.2M 2026-06
BioMarin Pharmaceutical USD 1.66B 870.84M 2026-06
Cipla INR 70.14B 7.16B 2026-03
Clal Biotechnology ILS 6.66M 3.75M 2023-12
Compugen USD 22.04M 533K 2026-03
CSL USD 4.61B 207M 2025-12
Eli Lilly USD 47.74B 11.11B 2026-06
Gilead Sciences USD 11.02B 1.54B 2026-06
GlaxoSmithKline GBP 21.53B 895M 2026-06
Grifols EUR 2.37B 156.97M 2025-12
Merck USD 27.73B 786M 2026-06
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Pfizer USD 32.65B 1.7B 2026-06
Roche Holding CHF 28.85B 846M 2026-06
Sarepta Therapeutics USD 502.91M 3.74M 2026-06
Ultragenyx Pharmaceutical USD 351M 26M 2026-06
X T L Biopharmaceuticals USD 420K 341K 2025-12